Alpha Teknova, Inc. (TKNO)

Over the past six months, Alpha Teknova's stock has been impacted by several earnings reports and related announcements. On May 7, 2026, Alpha Teknova reported its First Quarter 2026 financial results, with revenue increasing by 13% year-over-year to $11.1 million, and the stock declined 2.67%. On April 22, 2026, Teknova announced it would report First Quarter 2026 financial results on May 6, 2026. On February 26, 2026, Teknova reported its Fourth Quarter and Full Year 2025 financial results, and TKNO shares gained +0.9% the day after. On February 5, 2026, Teknova announced it would report Fourth Quarter and Full Year 2025 financial results on February 26, 2026. On November 6, 2025, Teknova reported its Third Quarter 2025 financial results. On October 28, 2025, Teknova announced it would report Third Quarter 2025 financial results on November 6, 2025. Insider buying activity was noted, with the President and CEO, Stephen Gunstream, buying 26,000 shares at $2.15 on March 6, 2026.

Alpha Teknova has indicated that its quarterly results may remain "lumpy," particularly within its Clinical Solutions segment, due to larger average order sizes and uneven timing of these orders. The company's management has framed recent revenue rebounds as evidence of demand gradually normalizing after a difficult funding cycle for customers in the life sciences sector.

Alpha Teknova, Inc. is a life sciences company that produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company operates in the professional, scientific, and technical services sector, specifically in testing laboratories, and is also categorized under the healthcare sector and drug manufacturers. Teknova's product offerings support customers across various research and clinical workflows, including molecular diagnostics, synthetic biology, emerging therapeutic modalities, and cell therapy development. The company provides customizable solutions, from research use only to good manufacturing practice stages, to help customers scale their processes. Major product categories include agar plates, microbial culture media and supplements, cryopreservation media, buffers and reagents, and water. These products are categorized into "Lab Essentials" and "Clinical Solutions."

Alpha Teknova, Inc. derives its key revenue primarily from the United States. The company's corporate office is located in Hollister, California, United States. It serves a broad range of customers, including pharmaceutical firms, biotech companies, contract manufacturers, and academic institutions, both in the United States and internationally.

Alpha Teknova is positioned as a critical supplier of reagents in the life sciences industry, emphasizing agility, customization, and the ability to deliver high-quality, custom, made-to-order products with short turnaround times. Analyst sentiment around Alpha Teknova is largely optimistic, with a consensus rating of "Hold" and an average rating score of 2.33. The company's Q1 2026 earnings call struck an upbeat tone, highlighting a return to double-digit revenue growth and improved gross margins, suggesting a gradual normalization of demand after a difficult funding cycle for customers in the life sciences sector.

Alpha Teknova, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. As of April 29, 2026, the company had 74 institutional owners and shareholders holding a total of 7,051,098 shares. Major institutional owners include Roubaix Capital, LLC, Balyasny Asset Management Llc, UBS Group AG, BlackRock, Inc., Vanguard Group Inc, Conestoga Capital Advisors, LLC, Royce & Associates Lp, Geode Capital Management, Llc, Bank Of America Corp /de/, Massar Capital Management, LP, State Street Corp, Bank of New York Mellon Corp, and Northern Trust Corp. The largest individual Alpha Teknova shareholder is Telegraph Hill Partners IV LP, owning 25.62 million shares, representing 47.81% of the company. Other significant insider owners include Irene Davis and Ted Davis, each holding 3,575,559 shares (6.67%).